ViroGates (VIRO) Q2 2025 earnings summary

Executive summary

• H1 2025 marked by low customer activity and an ongoing transition from acute care to the general health and longevity market.

• Revenue declined 18% year-over-year to DKK 1.9m, but other income from partnerships, especially with Sobi, offset some of the decline.

• Strategic focus on expanding suPARnostic® applications in longevity and preventive health, with proof-of-concept for a new POC+ device.

• Recurring customer base increased to 19, up from 17 in H1 2024.

Financial highlights

• Revenue: DKK 1,869k, down 18% from H1 2024.

• Operating loss: DKK -5,871k, improved by 26% year-over-year.

• Net loss: DKK -6,031k, a 22% improvement from H1 2024.

• Gross profit: DKK 3,615k, up 118% due to higher other income.

• Cash and cash equivalents: DKK 11,804k at period end, up from DKK 8,736k.

Outlook and guidance

• Full-year 2025 guidance maintained: revenue of DKK 5–7m and EBIT of DKK -8m to -11m.

• Anticipates results from longevity market efforts, especially in the US, in H2 2025.

• Sobi collaboration for US and EU market clearance ongoing; revenue impact expected from 2026.